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Abstract 
Objectives: (1) Compare pharmacists’ self-assessed knowledge of migraine before and after an educational intervention; (2) Compare 
pharmacists’ self-reported care behaviors following an educational intervention with a control group of pharmacists; (3) Identify 
interactions between the educational intervention results and individual independent variables. Design: Quasi-experimental, parallel 
design. Setting: Twenty community pharmacies in northeastern Oklahoma from March to May 2010. Participants: 49 pharmacists at 
one of twenty community pharmacies, with active and in-good-standing Oklahoma pharmacy licenses. Intervention: Two-hour 
educational session on migraine identification and current treatment. Main outcome measures: Compare pharmacists’ self-assessed 
knowledge of migraine before and after an educational intervention and compare self-reported care behaviors of these same 
pharmacists with a control group of pharmacists. Results: Pharmacists’ self-assessed knowledge mean scores were significantly 
higher post-intervention compared to pre-intervention (p<0.0001).  Self-assessed knowledge was higher in the intervention group 
post-questionnaire scores compared to the control group of pharmacists (p=0.004). Intervention group pharmacists were more 
confident in their ability to maintain knowledge of migraine (p=0.04). No difference was seen regarding difficulty in providing care for 
a migraineur (p=0.16) or in how the pharmacists perceived employer culture (p=0.79). No significant interactions were found 
between the educational intervention and demographic variables collected. Conclusion: Attending an educational program on 
migraine improved pharmacists’ knowledge and confidence when providing care to migraineurs.  
 
 
Introduction 
Migraine is a common, chronic, disabling condition 
characterized by recurrent episodes of headache 
accompanied by debilitation, nausea, vomiting, photophobia, 
and phonophobia. Estimations show that approximately 12% 
of adults in the United States suffer from migraines.1,2 
Evidence in this area suggests that migraine is not well 
managed in primary care, with only about 50% of migraineurs 
consulting their physician concerning this condition.2-4 
Physicians incorrectly diagnose 50% of migraineurs, and many 
patients who are correctly diagnosed receive sub-optimal 
treatment, making migraine an underdiagnosed and 
undertreated condition.3,5-8 Because of this, some patients  
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with recurrent headaches may actually be suffering from 
undiagnosed migraines.  
 
Pharmacists have been successful in the management of 
various chronic diseases including diabetes,9 hypertension,10 
and asthma11. Migraine is also chronic in nature. However, 
few have examined pharmacists’ involvement specifically 
with recurrent headache sufferers such as migraineurs. 
Community pharmacists in particular are very accessible 
healthcare professionals and have the opportunity to interact 
with diagnosed and undiagnosed migraine sufferers.12 
Chronic headache sufferers approach community pharmacists 
in the United States 14 million times a year for a 
recommendation for an over-the-counter (OTC) medication 
for their headaches.12 A recent study in a community 
pharmacy investigating headache sufferers seeking OTC 
medications for headache identified underdiagnosis of 
migraine, underutilization of migraine prophylactic agents 
and triptans, and overuse of medication in that population.13 
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In addition, the majority of migraine sufferers are not 
satisfied with their current therapy.7 These trends suggest 
that pharmacists may be in an ideal position to improve 
migraineur outcomes through providing headache sufferer 
triage, pharmacologic and non-pharmacologic treatment 
recommendations, and patient counseling.   
 
Appropriate education is necessary for healthcare 
professionals to successfully manage disease states. 
Pharmacists who have completed a training program in 
pharmaceutical care with an emphasis on pain have been 
shown to make a positive impact on headache and migraine 
sufferers’ mental health and self-efficacy.14 Ideally, all 
healthcare professionals, including pharmacists, who come in 
contact with recurrent headache sufferers should be 
educated on migraine identification and treatment 
approaches. As very accessible healthcare professionals with 
extensive knowledge and training, community pharmacists 
are in an ideal position to combat recurrent headache 
sufferer underconsulting, underdiagnosis, and 
undertreatment. Even though community pharmacists 
possess the tools necessary to make a positive impact on 
chronic headache sufferers, many of them are not well versed 
in migraine identification or current migraine treatment 
guidelines.15 An educational intervention in the form of a 
continuing education (CE) program is a good option to allow 
pharmacists a chance to practice their skills in working with 
recurrent headache sufferers.  
 
The Pharmacists’ Care of Migraineurs Scale (PCMS), a valid 
and reliable instrument, was developed as a tool for 
documenting pharmacists’ care of migraine sufferers and 
identifying factors associated with the quality of the care 
provided.16 Pharmacists’ self-reported knowledge of migraine 
was found to be a key factor and  accounted for 38% of the 
variance in responses in the PCMS.17 The areas of the 
instrument used in the PCMS study that addressed self-
assessed knowledge of migraine were multi-faceted and 
included treatment guidelines, non-pharmacologic 
management of migraine, abortive and preventative 
pharmacologic therapies, as well as prescription drug therapy 
formulary issues and costs of oral triptan therapies.16,17 In this 
study, the researchers hypothesized that pharmacists with 
additional and comprehensive education targeting migraineur 
care, delivered as a CE program, would report improved 
migraine knowledge and provide higher quality care to 
migraine sufferers. Consequently, these pharmacists may be 
able to positively impact chronic headache sufferers’ 
outcomes. The researchers also hypothesize that no 
difference will be seen with regard to the educational 
intervention and any independent variables, such as sex, age, 
or history of migraine headaches. 
Objectives 
The objectives of this study were to: 
(1) Compare pharmacists’ self-assessed knowledge of 
migraine before and after an educational 
intervention;  
(2) Compare pharmacists’ self-reported care behaviors 
following an educational intervention with a control 
group of pharmacists;  
(3) Identify inter- and intra-group interactions between 
the educational intervention results and various 
individual independent variables.   
 
Methods 
Sample population/recruitment 
The sample was selected from a regional chain of community 
pharmacies located in northeastern Oklahoma.   
 
Pharmacists were eligible for inclusion if they were a current 
pharmacist at one of 20 community pharmacies in the 
regional chain and if they had an active and in good standing 
Oklahoma pharmacy license. Excluded from the study were 
relief pharmacists and those who failed to complete the 
surveys.   
 
The pharmacists were made aware of the educational 
program through direct recruitment, fliers, and emails. If 
pharmacists in a given location were interested in 
participating in the educational program, all pharmacists from 
that store were assigned to the intervention group. 
Conversely, if the pharmacists for that location were neither 
interested nor able to participate in the intervention, they 
were asked to participate in the control group. Individual 
pharmacies were selected based on convenience and 
geographic proximity to where the educational program 
would be held. A replacement strategy using store proximity 
was used to reach the desired sample size of 10 pharmacies 
in both the intervention and control groups. Based on 
estimates from the pharmacy chain’s upper management, the 
researchers expected approximately 2.5 pharmacists per 
store and thus a sample size of 25 pharmacists in each group.   
 
Approval for the project was obtained from the University’s 
institutional review board.  Informed consent was obtained 
from all project participants.   
 
Research design and procedures 
This study used a quasi-experimental, parallel design. 
Questionnaires gathering demographic and migraine specific 
information were administered to the intervention group of 
pharmacists at baseline just prior to their participation in a 
two-hour educational course on migraines. One month 
following the educational program, the same pharmacists 
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were hand-delivered and asked to complete the same 
questionnaire within a two-week time frame. Pharmacists in 
the control group completed their only questionnaire at the 
same time the intervention pharmacists completed their 
follow-up.   
 
Not all pharmacists in a store were available to attend an 
educational program at the same time, so the program was 
offered live on two separate dates and pre-recorded online. 
Pharmacists who were unable to attend either of the live 
programs were supplied with the baseline questionnaire, 
allowed time to fill it out, and provided a link to the online 
program. When the program was complete, the pharmacist 
was asked to submit assessment question responses to the 
educational program administrators to prove completion 
(and to confer CE credits). At one month from educational 
program completion, the second questionnaire was delivered 
and the pharmacist was allowed two weeks to complete and 
return it.   
 
Surveys were stamped with a numeric code known only to a 
participating research assistant. The research assistant had 
the ability to link survey questionnaire responses to individual 
respondents; however, this information was protected and 
precluded from disclosure to or use by the investigators.   
 
The intervention consisted of an Accreditation Council for 
Pharmacy Education (ACPE)-approved CE program given at 
the University of Oklahoma Health Sciences Center, Tulsa 
Campus on March 6 and 7, 2010. The program was primarily 
didactic and covered migraine pathophysiology, screening 
headache patients, migraine triggers, pharmacotherapy for 
treatment and prevention of migraines, and non-
pharmacologic recommendations for migraineurs. The 
program contained pharmacotherapy pearls important for a 
community pharmacist, and it also mirrored the many facets 
of the PCMS tool the investigators used for data collection. 
Active learning components (e.g., case studies to strengthen 
knowledge retention and flowcharts for acute and preventive 
migraine therapy selections) were incorporated to strengthen 
recommendation clarifications for the intervention group 
pharmacists. The pharmacist leading the sessions was a 
migraine expert who works with migraine patients on a daily 
basis and has substantial experience delivering migraine 
educational programs.    
 
Pharmacists who participated in the educational program 
received a meal during the program, two hours of CE credit, 
and a $50 gift card. Pharmacists in both the intervention and 
control groups received $5 gift cards when the surveys were 
delivered one month after the program was held.   
 
Instruments 
Demographic information considered to be potentially 
associated with the outcomes of interest was gathered for 
each participating pharmacist. Information gathered included 
gender, age, years as a community pharmacist, years with 
current employer, and presence/absence of migraines. 
 
The PCMS16, a validated survey used to assess self-reported 
care behaviors, is divided into 6 different parts: (1) perceived 
difficulty in providing care to recurrent headache sufferers, 
(2) perceived self-efficacy or level of confidence in providing 
care to recurring headache sufferers, (3) employer culture, (4) 
self-assessed knowledge of migraine, (5) actual care provided 
to recurring headache sufferers, and (6) ability to maintain 
knowledge of migraine. Each part of the PCMS was included 
in the survey provided to intervention and control group 
pharmacists, and the scales of assessment are described 
below.   
 
Part one, perceived difficulty, and part two, perceived self-
efficacy or level of confidence, were each assessed using 9 
items measured on a 7-point Likert-type18scale of agreement. 
Parts one and two are related but unique components of 
perceived behavioral control, part of the theory of planned 
behavior and demonstrate importance in predicting 
pharmacists’ job performance behaviors.19 Perceived 
organizational culture, part three, is measured with 3 items 
using a semantic differential scale anchored with patient and 
product for orientation, quality and quantity for focus, and 
professional and technical for pharmacists’ work.20 Part four, 
self-assessed knowledge of migraine, is measured using 12 
items on a 5-point Likert-type scale of agreement. Parts five 
and six comprise the previously validated PCMS portion of 
the questionnaire. The PCMS is a 41-item instrument 
measuring seven unique domains of pharmacists’ care 
provided to recurrent headache sufferers, including: 
empathy, prospective drug utilization review (DUR) of newly 
diagnosed migraineurs, medication counseling, 
nonpharmacologic treatment plan, headache sufferer triage, 
dissemination of public health information, and maintenance 
of migraine knowledge.  
 
Data analysis 
Internal consistency reliability of the overall multiple-item 
multiple-scale survey instrument and each individual part of 
the survey was assessed using Cronbach’s alpha (α). A 
Cronbach’s alpha of 0.7 or higher is generally viewed as 
indicating acceptable reliability, but in the case of exploratory 
studies, 0.6 or higher is considered acceptable.21 An a priori 
power analysis was completed, and it was determined a 
sample size of 25 pharmacists per group would be sufficient 
to detect a 10 point difference in score with 80% power, 
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using an unpaired t-test with an alpha level of 0.05. 
Descriptive statistics were produced to quantify socio-
demographic characteristics of the participants collectively 
and by group.  Associations between variables were explored 
using unpaired t-tests, Mann-Whitney U, chi-square, or 
Fisher’s exact tests, as appropriate. Intervention pharmacists’ 
pre-education knowledge scores, part four, were compared 
to the post-education knowledge scores from the same group 
of pharmacists using a paired t-test. Parts five and six were 
separately tabulated from intervention group pre- and post-
education surveys and a Student’s t-test was used to compare 
them to scores tabulated from control group surveys. Parts 
one, two, and three of the survey were handled in the same 
manner as parts five and six, including tabulations and 
comparisons. Additionally, scores were tabulated separately 
for each part of the survey and correlation coefficients were 
produced for each pairwise comparison in order to identify 
any potential associations between the sections. All analyses 
were performed using SAS v9.3 (SAS Institute, Cary, NC) with 
an alpha level of 0.05. 
 
Results 
Patient demographics 
A total of 49 pharmacists were included in the study, with 24 
in the intervention group and 25 in the control group. All 
pharmacists enrolled completed the study. Additional 
demographics and population characteristics are summarized 
in Table 1.   
 
Self-assessed knowledge of migraine 
The first objective of the study was to compare pharmacists’ 
self-assessed knowledge of migraine before and after an 
educational intervention addressing migraine identification 
and treatment. All 24 pharmacists assigned to the 
intervention group participated in the educational program 
and completed the required surveys. There was a significant 
increase between pre- and post-intervention scores on 10 of 
the 12 items related to knowledge, most notably, non-
pharmacologic management of acute headaches, the role of 
complementary and alternative therapies in the treatment of 
migraine, the role of prescription drugs in migraine 
prophylaxis, distinguishing migraine from other types of 
headache, and formulary status of various migraine 
treatments. (Table 2) In addition, average post-intervention 
cumulative knowledge score (43.8) was significantly higher 
than that of pre-intervention (34.4), with the post-
intervention survey an average 9.4 points higher than the 
pre-intervention survey (p<0.0001).    
 
Pharmacists in the intervention group showed no significant 
difference in pre- and post-intervention responses to items 
regarding knowledge of the role of prescription drugs in acute 
migraine therapy and knowledge of the cost to patients of 
various migraine treatment modalities (p=0.08 and p=0.41, 
respectively).   
 
Self-reported care behaviors and ability to maintain 
knowledge of migraine (PCMS) 
The second objective of the study was to compare self-
reported care behaviors from a post-education survey of 
pharmacists to a group of control pharmacists. While there 
was no difference in average cumulative score between pre-
education intervention pharmacists and control pharmacists 
(p=0.34), the mean post-education score of intervention 
pharmacists was 18.9 points higher than that of control 
pharmacists (p=0.004). (Table 3) 
 
When caring for recurrent headache sufferers, survey part 
five, pharmacists showed no difference in empathic 
responses when comparing the control and intervention 
groups. Pharmacists in the intervention group who were 
trained on triaging patients with possible migraines did score 
higher when asked about screening for drug-drug interactions 
and potential drug-related problems when filling a new 
migraine prescription (p=0.002 and p=0.03, respectively). 
Pharmacists who underwent the educational program were 
more likely to enlist family support (p=0.03), determine if a 
headache was a migraine (p=0.02), educate staff to alert the 
pharmacist when a headache sufferer presented to the 
pharmacy counter (p<0.0001), and conduct a medication 
history for a migraineur (p=0.002). Pharmacists also reported 
higher scores with regard to medication counseling, 
developing a nonpharmacologic treatment plan such as using 
a migraine diary, discussing trigger management and the role 
of complementary and alternative medications. (Table 3) 
 
Part six of the survey addressed ability to maintain knowledge 
of migraine. The comparison between the average 
cumulative score of the post-educational survey taken by 
intervention pharmacists and the average cumulative score of 
control pharmacists showed that the intervention 
pharmacists had an average score that was 2.0 points higher 
than the control pharmacists (p=0.04). Pharmacists in the 
intervention group were more likely to attend live CE 
programming on migraines (p=0.04) and seek information on 
the internet regarding migraine headaches (p=0.04). (Table 4) 
 
Perceived difficulty, level of confidence, and employer culture 
Analysis of survey part one, perceived difficulty in providing 
care to recurrent headache sufferers, resulted in no 
difference in mean cumulative score for post-education 
intervention group compared to control group (p=0.16). 
There were no statistically significant differences in scores for 
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individual questions. The survey instrument is available 
online. See supplemental information for this study.   
 
Self-efficacy (level of confidence) in providing care to 
recurring headache sufferers was assessed in part two of the 
survey by asking participants to rate their level of confidence 
in performing nine functions on a scale of 1 to 7, where one 
equaled not at all confident and seven represented extremely 
confident. The pre- and post-intervention group means were 
compared, revealing a significant difference between scores 
on the intervention group’s post-education survey, with an 
average of 49, and the control group’s survey, with an 
average of 42.3 (range:9-63, p-value=0.03). Out of the nine 
questions asked, the two that resulted in significant 
differences between groups addressed conducting DURs for 
newly diagnosed migraineurs (p=0.03) and triaging patients 
complaining of recurring headaches (p=0.003).   
 
Results of part three, assessing employer culture, showed no 
significant difference in cumulative mean score or mean 
score for individual questions when comparing the 
intervention group post-education survey results to the 
control group survey results (cumulative p-value=0.79). 
(Figure 1) 
 
Part four compared intervention and control pharmacists’ 
self-assessed knowledge of migraine. Pharmacists in the 
intervention group reported a higher knowledge of 8 out of 
12 items. The group mean scores were 43.8 for the 
intervention group and 35.8 for the control group on a scale 
of 12-60 (p<0.0001). (Table 2)   
 
Examination of reliability and validity 
The assessment of the overall test instrument resulted in a 
Cronbach’s alpha (α) of 0.94. Additionally, each of the six 
parts of the survey (perceived difficulty: α=0.88, level of 
confidence: α=0.94, employer culture: α=0.85, knowledge: 
α=0.90, care behaviors: α=0.96, and maintenance of 
knowledge: α=0.62) showed acceptable individual reliability. 
Item deletions failed to result in any substantial improvement 
in reliability. The study design did not include multiple 
administrations of the instrument for data collection to be 
used in an analysis of test-retest reliability and the 
intervention and control group means were not available to 
test validity beyond face validity (110.4 versus 91.5, 
respectively). (Table 3) 
 
Analysis of correlation and interaction 
Correlation matrices were produced for each survey 
administered examining potential relationships between 
survey sections and the independent variables age, gender, 
years as a community pharmacist, years with current 
employer and history of migraines. No correlations were 
found when analyzing control group surveys (n=25). A 
moderate positive correlation (p=0.04, p=0.05) between self-
reported care behaviors and age was found in both the pre- 
and post-education surveys administered to the intervention 
group (n=24). Further investigation identified no associations 
between age and the remaining demographic variables and 
confirmed no significant change in comparison of outcomes 
of interest related to age. The individual location of each 
pharmacist was not considered to be a variable of interest 
during the design phase of the study and was not 
documented during data collection; therefore no analysis of 
potential within store correlation was performed. No 
significant interactions were found between the educational 
intervention and the demographic variables age, gender, 
years as a community pharmacist, years with current 
employer, or history of migraine headaches.    
 
Discussion 
Community pharmacists are in a position to positively impact 
the care of recurrent headache sufferers by staying up-to-
date on the current migraine treatment recommendations 
through educational programs and intervening when a 
patient presents to the pharmacy counter with the complaint 
of headache. Attending an educational program on migraine 
improved pharmacists’ self-assessed knowledge of migraine, 
between both pre- and post-intervention as well as post-
intervention and control. The gains in knowledge of the 
intervention group post survey can be directly related back to 
the educational program in which the pharmacists 
participated. The educational program raised awareness of 
different topics specific to recurrent headache sufferers. It 
focused on migraine therapies, reminding pharmacists of the 
nuances of each drug class, but it also developed problem 
solving skills such as what medication to recommend in 
certain patient case scenarios. The program gave pharmacists 
hands-on practice in making recommendations through these 
cases, and the pharmacists left with flowcharts developed by 
the presenters of what medications to recommend in certain 
situations of preventive and acute care of migraine patients. 
In addition to the in depth medication review, the program 
also illustrated how to triage a patient at the pharmacy 
counter with headache or migraine, recommending further 
work-up from a physician as well as how to educate patients 
on the management of migraine triggers. Because of the 
program, the theoretical gains in the areas of knowledge 
positively impacted specific topics of triggers, diet and 
exercise, non-pharmacologic management of headaches, OTC 
medications, complementary and alternative therapies, 
preventive therapies, medication interactions, specific 
guideline recommendations, distinguishing migraine from 
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other headaches and formulary status of migraine 
treatments.  
 
Interestingly, however, pharmacists did not show a gain in 
knowledge regarding the role of acute therapies for migraine 
and the cost of such therapies. The researchers hypothesized 
pharmacists in the intervention group gained no additional 
knowledge about these topics compared to the control group 
pharmacists since acute migraine therapies are a common 
focus for pharmacy school curricula22 and no research is 
available on if colleges of pharmacy teach the costs of these 
more expensive therapies (e.g. triptans), which could explain 
this lack of significance. Cost of medications was not a focus 
of the educational program presented. Conversely, it can be 
postulated that the control pharmacists may have had a 
better understanding of these components of migraine 
therapy.   
 
The care of a migraineur is more complicated than simply 
what medication to prescribe. Pharmacists who gain 
knowledge gain one of the many tools necessary to positively 
impact care of patients who suffer from chronic diseases such 
as migraine. It is important to note that just improving 
knowledge does not always translate into improving 
pharmacy practice activities. A study by Maio et al. evaluating 
the effectiveness of pharmacy CE programs showed that 
symposium-type programs were the most effective at 
enhancing knowledge. The results also showed that despite 
all programs being effective, no CE format was effective in 
helping pharmacists change clinical practice behaviors.23 A 
program that successfully changes practice behaviors should 
consist of a variety of CE formats, including but not limited to 
didactic teaching, reading and handouts, hands-on activities 
and practice. The program developed for this project 
contained all of these elements, supporting the positive 
results seen post-intervention on the pharmacists’ care 
behaviors. 
 
In order to put into use the knowledge gained in an 
educational program, a pharmacist must not perceive the 
task to be too difficult and have confidence in their abilities to 
properly care for a patient. An educational program helps 
teach a pharmacist the knowledge needed, but confidence in 
applying the knowledge to a patient cannot be assumed 
simply by learning the material. The study population showed 
that the groups of pharmacists did not differ in the perceived 
difficulty in providing care to patients who suffer from 
migraines; however, the intervention pharmacists did show 
an increase in confidence to provide such care to patients 
post-intervention. Although pharmacists did not find 
providing this care difficult, many lacked the confidence to 
actually approach the care of a migraineur until this 
educational program. This program demonstrated positive 
outcomes to help eliminate barriers for pharmacists. Armed 
and provided with specific knowledge about migraine 
management, the researchers theorized these pharmacists 
will put into practice what they have learned about the 
management and care of this patient population. 
 
The culture of the employer group is an important facet to 
providing care to patients. It can be presumed that if a 
pharmacist feels more supported to leave the pharmacy to 
discuss headache treatments with a recurrent headache 
sufferer, he/she will be more likely to do so. The results of 
the organizational culture questions showed that the groups 
viewed the organization similarly in the aspects of 
orientation, focus, and pharmacists’ work priority, thus 
minimizing the chance that the intervention pharmacists 
viewed their culture differently than the control pharmacists.  
 
After knowledge, confidence, perceived difficulty, and 
employer culture were assessed, the next step was to look 
into the actual care provided to recurrent headache sufferers. 
The PCMS results showed that pharmacists in the 
intervention group scored cumulatively higher in the 
categories of actual care provided to recurrent headache 
sufferers, which were broken down into the factors of 
empathy, prospective DUR, headache sufferer triage, 
medication counseling, nonpharmacologic treatment plan, 
dissemination of public health information, and maintenance 
of knowledge on migraine. Pharmacists reported screening 
for drug-drug interactions and other drug-related problems 
more often in this population, possibly because these 
interactions were highlighted in the educational program. 
Patient triage was also highlighted in the educational 
program, including a quick 3-question screening tool called 
the ID-Migraine that a community pharmacist could use daily 
when a patient presents to the pharmacy counter with a 
headache.24 This was discussed as something simple and not 
time-consuming a community pharmacist can do to change 
their clinical practice behaviors and get headache sufferers 
thinking more about what type of headache they may be 
having. The program also raised awareness of the importance 
of having staff alert the pharmacists if someone presents to 
the counter with a complaint of headache, another 
intervention highlighted in the educational program. 
Counseling practices improved for the intervention group as 
well, along with the nonpharmacologic recommendations for 
a person suffering with recurrent headache like keeping a 
headache diary, avoiding triggers, and the role that OTC 
medications play in prevention and management of migraine.   
 
The importance of the timing of the survey deployment in 
this project should not go overlooked. Immediately after an 
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educational intervention the participants were expected to 
demonstrate more post-presentation knowledge than prior 
to the program.  One month after the program the 
knowledge and practices learned were still being employed. 
The educational intervention and the post-surveys were 
spaced by one month to evaluate whether short-term 
retention of migraine knowledge and clinical practice skills 
were present. The results revealed retention did occur up to 
this one-month mark. This showed that one month after an 
educational intervention, pharmacists provide care to 
headache sufferers at a higher level than those that did not 
attend an educational programming on migraine headaches.   
 
Limitations 
Quasi-experimental research has limitations, including not 
being able to truly control for confounders.25 The researchers 
controlled for confounders by group randomization of 
pharmacies, and also by excluding pharmacists who worked 
at multiple locations, thus attempting to eliminate the chance 
of knowledge from the CE program traveling from 
intervention store to control pharmacists.   
 
Although the research had enough power to detect a 
significant difference between groups, the sample size was 
still small.  Because of the groups’ sizes, this study can serve 
as the pilot for a larger scale study to further define the 
impact of such an intervention for community pharmacists.   
The results of this study may only be applicable to the 
population in which the intervention was conducted, which 
was a regional community pharmacy chain in northeastern 
Oklahoma. In addition, the convenience sampling may not be 
truly representative of the general population of pharmacists 
even in this area. Two elements of the study design may have 
allowed for the introduction of selection bias into the study. 
First, by basing group assignment on pharmacist preference 
rather than random placement, it is possible that the 
intervention group was composed of pharmacists who were 
more motivated than pharmacists in the control group.  
Second, the incentives offered for participation, although 
viewed as a potential means of partially correcting non-
response bias, may have influenced individual inclination 
toward participation or non-participation. Also, the 
researchers relied on pharmacists to self-report behaviors, 
which have the potential to be inflated in the intervention 
group, introducing self-reporting bias into the results.  
 
Contamination bias is a potential concern when conducting 
an educational intervention study comparing intervention 
and control groups. This study involved an inherent 
opportunity for pharmacists in the intervention group to 
share knowledge acquired at the educational course on 
migraines with pharmacists in the control group, potentially 
decreasing the difference between the groups and resulting 
in a loss of study validity. In order to control for this, it was 
necessary to minimize contact between pharmacists in the 
two groups in the work environment. This was accomplished 
by assigning all pharmacists from a single location to only one 
of the two groups and excluding from participation any 
pharmacist reasonably expected to work at more than one of 
the pharmacies during the course of the study, although 
complete protection from contamination bias was not 
guaranteed with this method.   
 
The educational intervention was offered twice, but the 
sections occurred on a Saturday and Sunday of the same 
weekend. This could have posed an attendance issue since it 
is a common practice for community pharmacists scheduled 
to work on a given weekend to work both days. For those 
who were unable to attend a recording of the educational 
program was made available online, and it is possible that the 
study results were skewed due to differences in individual 
learning styles and availability for attendance at live 
educational sessions. Also, those that participated in the 
online viewing of the program may have been able to confer 
with colleagues that already attended the program live or 
completed it online to ask for help with assessment 
questions.  
 
Future Directions  
Recreating this study can help substantiate the impact seen, 
not only increasing enrollment but also studying more diverse 
populations of pharmacists of multiple states, employers, and 
disciplines (e.g. community pharmacy, ambulatory care, 
health-systems pharmacists).  Future studies should also 
determine long-term effects of the educational intervention 
on the actual care provided by pharmacists for recurrent 
headache sufferers, evaluating continuing positive effect of 
the intervention after a year or longer. Moreover, future 
research should focus on data gathered from migraineurs 
about their perceptions of the care received from 
pharmacists trained in headache and migraine management. 
Valuable insights might also be achieved by evaluating 
outcomes based on intervention delivery method used.  
 
Conclusion 
Attending an educational program on migraine improved 
pharmacists’ knowledge, confidence, and clinical practice 
behaviors when providing care to migraineurs and recurrent 
headache sufferers. This study demonstrated that focused 
educational initiatives increased patient counseling activities 
in the cohort of pharmacists participating in the initiative and 
caring behaviors toward the migraineur population.  
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Table 1:  Demographics 
 
Variable Control (n=25) Intervention (n=24) p-value 
Age, mean 46.5 47.7 0.74 
Male, n (%)  14 (56.0) 16 (66.7)  
Migraine sufferer, n (%) 4 (16.0) 5 (20.8)  
Community pharmacist, mean years 22.2 21.8 0.92 
Current employer, mean years 15.6 18.1 0.44 
 
 
 
 
Table 2: Pharmacists’ self-assessed knowledge of migraine: 
t-test results for differences in mean score for each question 
 
Question 
Intervention 
(n=24) p-value Control (n=25) p-value 
Pre Post 
Potential triggers for migraine headaches/prevention of 
attacks 3.1 3.8 **0.0001 3.28 **0.007 
Role of diet/exercise/lifestyle in migraine prevention 2.7 3.6 **<0.0001 3.28 0.06 
Non-pharmacologic management of acute headaches 2.8 3.6 **0.0009 2.72 **0.005 
Role of OTCs 3.3 3.8 **0.004 3.44 0.06 
Role of complementary & alternative therapies 2.2 3.5 **<0.0001 2.60 **0.0005 
Role of prescription drugs in acute migraine therapy 3.7 4.0 0.08 3.68 0.07 
Role of prescription drugs in migraine prophylaxis 3.4 3.9 **0.02 3.36 **0.004 
Contraindications/potential interactions with drugs used 
in migraine therapy 3.1 3.8 **0.0003 3.08 **0.002 
US Headache Consortium treatment guidelines for 
migraine 1.8 3.5 **<0.0001 1.76 **<0.0001 
 Distinguishing between migraine and other headaches 3.0 3.8 **<0.0001 2.92 **0.0006 
Formulary status of various migraine treatments 2.3 3.1 **0.004 2.44 **0.04 
Patient cost of various migraine treatments 3.1 3.3 0.41 3.32 0.10 
Total 34.4 43.8 **<0.0001 35.8 **<0.0001 
  **statistically significant at α=0.05 
 
http://z.umn.edu/INNOVATIONS                         2014, Vol. 5, No. 4, Article 181                       INNOVATIONS in pharmacy   9 
 
Original Research PHARMACY PRACTICE 
 
Table 3:  PCMS Part 5: Actual Care Provided to Recurring Headache Sufferers 
 - t-test results for differences in mean score for each question 
 
Item 
Mean 
p-value 
Control 
(n=25) 
Intervention 
(n=24) 
Empathy 
1.1 Listen attentively to patients  3.36 3.33 0.91 
1.2 Provide empathic responses  3.76 3.67 0.74 
1.3 Establish rapport with patients  3.36 3.21 0.62 
Prospective DUR 
2.1 Contact prescriber if barriers to therapy exist   3.64 4 0.24 
2.2 Screen for drug-drug interactions  3.72 4.54 **0.002 
2.3 Screen new therapy for potential drug-related problems. 3.32 4.04 **0.03 
2.4 Identify adverse effects of therapy. 2.92 3.33 0.08 
2.5 Contact for prior authorization if maximum days of therapy/month is exceeded 3.56 4 0.17 
2.6 Contact prescriber to discuss alternatives/prophylaxis  2.16 2.75 0.06 
Headache Sufferer Triage 
3.1 Enlist the support of family or caregivers  1.52 2.13 **0.03 
3.2 Gather a patient’s history of recurring headache  1.68 2.21 0.07 
3.3 Attempt to determine whether the headache is a migraine 2.4 3.08 **0.02 
3.4 Refer a patient with a diagnosed, but unmanaged headache problem to a specialist  2.36 2.5 0.62 
3.5 Instruct staff to alert you of someone who complains about or requests a remedy for recurring headaches 1.76 3 **<0.0001 
3.6 Conduct a medication history review  2 2.96 **0.002 
Medication Counseling 
4.1 Provide counseling on proper directions for use, including the maximum dose per day/week. 2.84 3.58 **0.01 
4.2 Provide counseling on rebound headache 2.36 3.29 **0.002 
4.3 Provide counseling on possible adverse effects  2.96 3.46 0.09 
4.4 Provide counseling on the importance of adherence to prophylaxis regimen  2.84 3.38 0.07 
4.5 Inform patients receiving their first prescription for prophylaxis that they may not notice result right away.  2.48 3.08 **0.04 
4.6 Inform the patient that prophylaxis medication will not completely eliminate migraines 2.28 3.13 **0.004 
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4.7 Discuss effectiveness of therapies 2.72 3.04 0.24 
4.8 Look for signs of prophylaxis non-adherence  2.28 3 **0.004 
Nonpharmacologic Treatment Plan 
5.1 Recommend a headache diary 1.88 2.42 **0.04 
5.2 Discuss identification/avoidance of triggers 2.56 3.13 **0.03 
5.3 Discuss role of OTC medications 2.72 3.33 **0.04 
5.4 Discuss role of complementary/alternative medicines  1.88 2.63 **0.01 
5.5 Discuss non-pharmacologic adjunctive therapies for migraine attacks 2.44 2.96 0.05 
5.6 Determine effectiveness of nonpharmacologic therapies in ameliorating migraine attacks.  2.64 3.04 0.1 
5.7 Look for signs of ineffective migraine therapy   2.32 3.08 **0.004 
5.8 Discuss alternatives of ineffective therapy with patients 2.84 3.42 **0.03 
5.9 Refer patients to credible internet information  2.52 2.79 0.38 
Dissemination of Public Health Information 
6.1 Provide written information when dispensing a migraine prescription  2.08 2.92 **0.03 
6.2 Make brochures/pamphlets available  1.68 2 0.28 
6.3 Refer patients to educational materials  2.2 2.38 0.58 
6.4 Participate in screenings/migraine awareness programs 1.44 1.63 0.4 
 Average Cumulative Score 91.5 110.4 **0.004 
** Statistically significant at α=0.05 
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Table 4: PCMS Part 6: Ability to Maintain Knowledge of Migraine 
 - t-test results for differences in mean score for each question 
 
Item 
Mean 
p-value 
Control 
(n=25) 
Intervention 
(n=24) 
Maintenance of Knowledge on Migraine 
7.1 Attend live migraine education programming  2.36 3.04 **0.04 
7.2 Complete migraine self-study education  4.00 4.00 1.0 
7.3 Read research/review articles on migraine  2.40 2.88 0.20 
7.4 Seek migraine information from drug representatives  2.40 2.67 0.44 
7.5 Seek migraine information on the internet  2.80 3.42 **0.04 
 Average Cumulative Score 14.0 16.0 **0.04 
** Statistically significant at α=0.05 
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Figure 1: Comparison of average scores for questions assessing employer culture 
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 Pharmacists' Care of Recurring  
Headache Sufferers  
Page 2 
Value of Technician Certification Training Survey 
  
Extremely                                                                                 Extremely 
   Easy                                                                                         Difficult 
1. 
At my pharmacy demonstrating empathy to  
recurrent headache sufferers is… 
     1            2            3            4            5            6            7 
2. 
At my pharmacy conducting prospective DUR 
for newly diagnosed migraineurs is... 
     1            2            3          4            5            6            7 
3. 
At my pharmacy I find medication counseling for 
newly diagnosed migraineurs... 
     1            2            3            4            5            6            7 
4. 
Discussing non-pharmacologic treatment strate-
gies with migraine sufferers for me is... 
     1            2            3          4            5            6            7 
5. 
At my pharmacy monitoring drug therapy for 
migraine sufferers is... 
     1            2            3            4            5            6            7 
6. 
At my pharmacy advocating for the needs of 
migraine sufferers is... 
     1            2            3          4            5            6            7 
7. 
At my pharmacy conducting effective triage for 
patients complaining of headache is... 
     1            2            3            4            5            6            7 
8. 
At my pharmacy referring migraine sufferers to 
referent health information is... 
     1            2            3          4            5            6            7 
9. 
At my pharmacy maintaining current knowledge 
on migraine and migraine therapy is... 
     1            2            3            4            5            6            7 
   
Part I. Perceived Difficulty in Providing Care to Recurring Headache Sufferers. We would like to know the 
level of difficulty you face in providing care to recurring headache sufferers at the pharmacy you primarily 
work, given that pharmacy’s resources, or lack thereof.   Please record your answer on a scale from  
1 = Extremely Easy to 7 = Extremely Difficult.   
 Mig aine Survey: Appendix A
Part 2. Level of Confidence in Providing Care to Recurring Headache Sufferers. We would like to know 
the level of confidence you have in performing each of the following functions for migraine patients, regardless 
of which pharmacy you work in.   Please indicate your answer on a scale ranging from 1 = Not at all Confident 
to 7 = Extremely Confident. 
  
 Not at all                                                                                   Extremely 
Confident                                                                                   Confident 
10. 
Demonstrate empathy to potential and actual 
migraine sufferers. 
     1            2            3            4            5            6            7 
11. 
Conduct prospective DUR for newly diagnosed 
migraineurs. 
     1            2            3          4            5            6            7 
12. 
Provide medication counseling for newly diag-
nosed migraineurs. 
     1            2            3            4            5            6            7 
13. 
Discuss non-pharmacologic treatment strategies 
with migraine sufferers. 
     1            2            3          4            5            6            7 
14. Monitor drug therapy for migraine sufferers.      1            2            3            4            5            6            7 
15. Advocate for the needs of migraine sufferers.      1            2            3          4            5            6            7 
16. 
Effectively triage patients who complain of recur-
ring headaches. 
     1            2            3            4            5            6            7 
17. 
Refer migraine patients to pertinent disease 
management information.  
     1            2            3          4            5            6            7 
18. 
Maintain current knowledge on migraine and 
migraine therapy. 
     1            2            3            4            5            6            7 
   
Page 3 
Part 4. Self-assessed Knowledge of Migraine. Please self-evaluate your knowledge of the following aspects 
of migraine headache and its treatment using the scale below.  We ask that you be truthful and accurate as pos-
sible in your assessment. 
 1 = Not a all knowledgeable 
 2 = A little knowledgeable 
 3 = Fairly knowledgeable 
 4 = Very knowledgeable 
 5 = Completely knowledgeable 
  
 Not at all            A little            Fairly              Very          Completely 
knowledge-      knowledge-   knowledge-  knowledge-   knowledge- 
     able                  able      able              able                able 
22.  
Potential triggers for migraine headaches/
prevention of attacks. 
        1                 2                  3               4                5 
23. 
Role of diet, exercise, lifestyle in prevention of 
migraine. 
        1                 2                  3               4                5 
24. 
Non-pharmacologic management of acute head-
aches. 
        1                 2                  3               4                5 
25. The role of OTCs in migraine therapy.         1                 2                  3               4                5 
26. 
The role of complementary & alternative thera-
pies in the treatment of migraine. 
        1                 2                  3               4                5 
27. 
The role of prescription drugs in acute migraine 
therapy. 
        1                 2                  3               4                5 
28. 
The role of prescription drugs in migraine prophy-
laxis. 
        1                 2                  3               4                5 
29. 
Contraindications and potential interactions with 
drugs routinely used in migraine therapy. 
        1                 2                  3               4                5 
30. 
US Headache Consortium treatment guide-
lines for migraine headache. 
        1                 2                  3               4                5 
31. 
 Distinguishing between migraine and other types 
of headache. 
        1                 2                  3               4                5 
32. 
Formulary status of various migraine treatment 
modalities. 
        1                 2                  3               4                5 
33. 
Patient cost of various migraine treatment mo-
dalities. 
        1                 2                  3               4                5 
 Migraine Survey 
Part 3. Employer Culture. We would like to know how you might describe the culture of the pharmacy organi-
zation for whom you work, with regard to its orientation, focus, and the nature of pharmacists’ work. For each of 
these 3 areas, please place a checkmark [] in the appropriate space.  
  
How would you describe your pharmacy in terms of its:  (Place a check [] on each of the 3 
lines) 
  
  
19.    Orientation:                 |     |     |     |     |     |     |     |     |     |     |     |     |    |     
                                             Patient                                                        Product 
 
  
20.     Focus:                        |     |     |     |     |     |     |     |     |     |     |     |     |    | 
                                             Quality                                                        Quantity 
 
  
21.     Pharmacists’ Work:    |     |     |     |     |     |     |     |     |     |     |     |     |    |  
            Professional                       Technical 
  
 VValue of Technician Certification Training Survey 
alue of Technician Certification Training Survey 
Page 4 
 
34. 
Listen attentively to patients describe frustrations 
regarding their headache. 
        1                 2                  3               4               5 
35. 
Provide empathic responses to persons com-
plaining of migraine or other recurring headaches. 
        1                 2                  3               4               5 
36. 
Establish rapport with patients suffering from re-
curring headaches. 
        1                 2                  3               4               5 
37. 
Conduct a medication history review for a newly 
diagnosed migraine sufferer. 
        1                 2                  3               4               5 
38. 
Screen for drug-drug interactions before dispens-
ing a drug used in migraine therapy. 
        1                 2                  3               4               5 
39. 
Screen new migraine therapy prescriptions for 
potential drug-related problems. 
        1                 2                  3               4               5 
40. 
When dispensing a migraine patient’s first triptan, 
I provide counseling on the proper directions for 
use of the medication, including the maximum 
dose per day and maximum dose per week. 
        1                 2                  3               4               5 
41. 
When dispensing a migraine patient’s first triptan, 
I provide counseling on headache rebound. 
        1                 2                  3               4               5 
42. 
When dispensing a migraine patient’s first triptan, 
I provide counseling on the possible adverse ef-
fects of the medication. 
        1                 2                  3               4               5 
43. 
When a patient initially receives a prescription for 
migraine prophylaxis, I provide counseling on the 
importance of adherence to the regimen (taking 
the medication every day). 
        1                 2                  3               4               5 
44. 
I inform patients receiving their first prescription 
for migraine prophylaxis that they may not notice 
result right away.  
        1                 2                  3               4               5 
45. 
When a patient initially receives a prescription for 
migraine prophylactic therapy, I inform the patient 
that the medication will not completely eliminate 
his/her migraines. 
        1                 2                  3               4               5 
46. 
Provide written information on migraine (disease 
management, non-pharmacological) when dis-
pensing a prescription for migraine.  
        1                 2                  3               4               5 
47. 
I recommend to migraine sufferers that they use a 
headache diary to identify migraine patterns 
(frequency, severity, duration) and triggers. 
        1                 2                  3               4               5 
48. 
I discuss identification and avoidance of common 
migraine triggers with migraine patients. 
        1                 2                  3               4               5 
49. 
I discuss the role of over-the-counter medications 
in the management of migraine. 
        1                 2                  3               4               5 
50. 
I discuss the role of complementary & alternative 
medicines in the management of migraine 
        1                 2                  3               4               5 
    Never                                                                         Nearly All the 
      To               Rarely           Sometimes      Fairly           time to  
Very Rarely                                                     Often        All the time 
Migraine Survey 
Part 5. Actual Care Provided to Recurring Headache Sufferers. Please indicate the relative frequency in 
which you currently engage in the following behaviors at your primary pharmacy of employment.  Please provide 
the most truthful and accurate answer, in consideration of the constraints you face in practice and NOT HOW 
YOU MIGHT IDEALLY LIKE TO PRACTICE.  Please indicate your answer to each item below  (#s 34-69) using 
the following scale:  
 1 = Never to Very Rarely 
 2 = Rarely 
 3 = Sometimes 
 4 = Fairly Often 
 5 = Nearly all the time to All the time 
Page 5 
 Training SurveyVValue of Technician Certification Training Survey 
51. 
I discuss non-pharmacologic adjunctive thera-
pies for migraine attacks (heat, cold, relaxation 
techniques, rest, etc.) with migraine patients. 
        1                 2                  3               4               5 
52. 
Discuss effectiveness of prescribed therapies 
for migraine. 
        1                 2                  3               4               5 
53. 
Identify any adverse effects or other drug-
related problems associated with patients’ mi-
graine therapy. 
        1                 2                  3               4               5 
54. 
Determine effectiveness of OTC, alternative & 
complementary medicine, and other adjunctive 
therapy in ameliorating migraine attacks.  
        1                 2                  3               4               5 
55. 
I look for signs that migraine therapy is not as 
effective as it could be (e.g., frequent use of 
OTC or prescription analgesics and triptans). 
        1                 2                  3               4               5 
56. 
I look for signs of non-adherence to migraine 
prophylaxis (e.g., late refills, increased  mi-
graine frequency and severity).  
        1                 2                  3               4               5 
57. 
Contact physician and/or health plan for prior au-
thorization if the migraineur needs more than the 
maximum number of medication as covered by the 
health plan.  
        1                 2                  3               4              5 
58. 
Discuss alternatives with patients whose migraine 
therapy is ineffective. 
        1                 2                  3               4              5 
59. 
I contact the prescriber to discuss alternatives or 
prophylaxis when acute migraine therapy is insuffi-
cient or ineffective (e.g., triptan is not working, 
patient uses triptan frequently, migraines particu-
larly severe and long in duration). 
        1                 2                  3               4              5 
60. 
Contact prescriber if patients’ prescribed therapy is 
not covered by insurance or whose cost may con-
tribute to noncompliance.  
        1                 2                  3               4              5 
61. 
Enlist the support of family or caregivers for 
patients suffering from migraine or recurring 
headaches.  
        1                 2                  3               4               5 
62. 
Gather a history of a consulting patient’s recur-
ring headache problem who has not yet seen a 
physician for the headache and make a referral, 
if necessary. 
        1                 2                  3               4               5 
63. 
Attempt to determine the nature of a consulting 
patient’s headache to determine whether it is 
migraine, or some other type of headache. 
        1                 2                  3               4               5 
64. 
Refer a patient with a diagnosed, but unmanaged 
headache problem to a specialist (e.g., neurolo-
gist).  
        1                 2                  3               4              5 
 Migra e
Part 5. Actual Care Provided to Recurring Headache Sufferers—CONTINUED. Please indicate the relative 
frequency in which you currently engage in the following behaviors at your primary pharmacy of employment.  
Please provide the most truthful and accurate answer, in consideration of the constraints you face in practice 
and NOT HOW YOU MIGHT IDEALLY LIKE TO PRACTICE.  Please indicate your answer to each item below  
(#s 34-69) using the following scale:  
 1 = Never to Very Rarely 
 2 = Rarely 
 3 = Sometimes 
 4 = Fairly Often 
 5 = Nearly all the time to All the time 
     Never                                                                          Nearly All the 
       To                 Rarely         Sometimes       Fairly          time to  
  Very Rarely                                                     Often      All the time 
Page 6 
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65. 
Instruct staff to alert you of someone who com-
plains about or requests a remedy for recurring 
headaches. 
        1                 2                  3               4              5 
66. 
Make brochures/pamphlets or other educational 
material about migraine available in kiosks or 
other areas free for public consumption. 
        1                 2                  3               4               5 
67. 
Refer patients to educational materials available 
at the pharmacy. 
        1                 2                  3               4               5 
68. 
Refer patients to credible information about mi-
graine on the internet. 
        1                 2                  3               4              5 
69. 
Participate in screenings or migraine awareness 
programs. 
        1                 2                  3               4              5 
Part 5. Actual Care Provided to Recurring Headache Sufferers—CONTINUED. Please indicate the relative 
frequency in which you currently engage in the following behaviors at your primary pharmacy of employment.  
Please provide the most truthful and accurate answer, in consideration of the constraints you face in practice 
and NOT HOW YOU MIGHT IDEALLY LIKE TO PRACTICE.  Please indicate your answer to each item below  
(#s 34-69) using the following scale:  
 1 = Never to Very Rarely 
 2 = Rarely 
 3 = Sometimes 
 4 = Fairly Often 
 5 = Nearly all the time to All the time 
     Never                                                                          Nearly All the 
       To                 Rarely         Sometimes       Fairly          time to  
  Very Rarely                                                     Often      All the time 
70. 
Attend live continuing education programming on 
migraine headache. 
        1                 2                  3               4              5 
71. 
Complete self-study continuing education on mi-
graine headache. 
        1                 2                  3               4               5 
72. 
Read original research or review articles on mi-
graine headache in peer-review journals. 
        1                 2                  3               4               5 
73. 
Seek information from drug sales representatives or 
medical/clinical liaisons on migraine headache. 
        1                 2                  3               4              5 
74. 
Seek information on the internet regarding migraine 
headache. 
        1                 2                  3               4              5 
       Not at          A little                                              
         all                 bit              Somewhat         A lot        Completely 
      like me         like me            like me          like me         like me 
Part 6. Ability to Maintain Knowledge of Migraine. We would like to know the extent of which you are able to 
remain abreast of current developments and issues in the treatment of migraine.  Use the following scale to de-
scribe your propensity to seek information on migraine.  
 1 = Not at all like me 
 2 = A little bit like me 
 3 = Somewhat like me 
 4 = A lot like me 
 5 = Completely like me 
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75. Your gender: (place an “x” or “”) 
 Male 
 Female 
    
76. Your age: 
 
_____ 
 
years 
  
77. How many years have you been practicing as a community pharmacist? 
 
_____ 
 
years 
  
78. How many years have you been with your current employer?  
 
_____ 
 
years 
  
79. Do you suffer from migraine headaches yourself? (place an “x” or “”) 
 
  Yes 
  No 
  
Part 7.  Personal and workplace information.  
Finally, if you could just tell us:   
 Migraine Survey 
 Thank you so much for your participation!! 
Please remember to return the completed survey to the        
research team in two weeks! 
